Cite
HARVARD Citation
Dhunputh, C. et al. (2022). Single‐dose (4.5 mg/m2) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia. British journal of haematology. pp. 373-381. [Online].